Login
Relay Therapeutics, Inc. logo

Relay Therapeutics, Inc.

relaytx.com

What Do They Do?

Develops small-molecule drug candidates for patients with cancer and genetic diseases, using computational and experimental methods to target genetically defined conditions.

How Do They Make Money?

Elevar pays Relay for global rights to develop and commercialize lirafugratinib, with payments at signing and when materials are transferred, plus milestones and royalties based on sales.

FY2025 revenue

Who Are Their Customers?

Elevar received global development and commercialization rights to lirafugratinib through an exclusive license; Relay retains those rights for its other active programs.

Do Revenues Turn Into Profits?

No. It lost $276.5M in FY2025.

Operating income, FY2025
−1972% of revenue
▲ +19% (Loss) vs FY2024 (−$372.5M, −3722%)
Net income, FY2025
−1801% of revenue
▲ +18% (Loss) vs FY2024 (−$337.7M, −3375%)
Free cash flow, FY2025
−1536% of revenue
▲ +6% (Loss) vs FY2024 (−$251.1M, −2509%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −10% (Loss)
vs −$74.1M in Q3 FY2025

Growing. Revenue grew 5.1x in 4 years, from $3M in FY2021 to $15.4M in FY2025, about 50% a year.

Licensing and ending programs The earlier report included a fibroblast growth factor receptor drug and a Genentech collaboration; the latest report says the former was licensed to Elevar and Genentech's agreement ended, with Relay stopping work on the latter.

Who Do They Compete With?

Competes with Novartis, AstraZeneca, Roche Holding, Celcuity, Totus Medicines, Eli Lilly and, OnKure, Kaken Pharmaceutical, Palvella Therapeutics, Pfizer, Revolution Medicines, Amicus Therapeutics, Sanofi, Takeda, and Protalix Biotherapeutics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support